The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements by Procaccini, Claudio et al.
ResourceThe Proteomic Landscape of Human Ex Vivo
Regulatory and Conventional T Cells Reveals
Specific Metabolic RequirementsGraphical AbstractHighlightsd Ex vivo human Treg cells are highly glycolytic and
proliferating
d Ex vivo human Tconv cells use fatty-acid oxidation (FAO) and
are non-proliferating
d In vitro proliferation of human Treg cells requires both
glycolysis and FAO
d In vitro proliferation of human Tconv cells relies mainly on
glycolysisProcaccini et al., 2016, Immunity 44, 406–421
February 16, 2016 ª2016 The Authors
http://dx.doi.org/10.1016/j.immuni.2016.01.028Authors
Claudio Procaccini,
Fortunata Carbone,
Dario Di Silvestre, ..., Antonio La Cava,
Pierluigi Mauri, Giuseppe Matarese
Correspondence
giuseppe.matarese@unina.it
In Brief
The proteomic signature of human Treg
and Tconv cells and their functional
specialization is poorly understood.
Matarese and colleagues identified
metabolic pathway signatures that
suggest a highly-tuned balance between
glucose and fatty-acid oxidation
impacting functions of in vitro versus
ex vivo human Treg and Tconv cells.
Immunity
ResourceThe Proteomic Landscape of Human
Ex Vivo Regulatory and Conventional T Cells
Reveals Specific Metabolic Requirements
Claudio Procaccini,1,11 Fortunata Carbone,1,11 Dario Di Silvestre,2 Francesca Brambilla,2 Veronica De Rosa,1,3
Mario Galgani,1 Deriggio Faicchia,4 Gianni Marone,4 Donatella Tramontano,5 Marco Corona,6 Carlo Alviggi,7
Antonio Porcellini,8 Antonio La Cava,9 Pierluigi Mauri,2,10 and Giuseppe Matarese1,5,*
1Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), 80131
Napoli, Italy
2Istituto di Tecnologie Biomediche, Consiglio Nazionale delle Ricerche (ITB-CNR), 20090 Segrate, Milano, Italy
3Unita` di NeuroImmunologia, IRCCS Fondazione Santa Lucia, 00143 Roma, Italy
4Dipartimento di Scienze Mediche Traslazionali e Centro Interdipartimentale di Ricerca in Scienze Immunologiche di Base Cliniche (CISI),
Universita` di Napoli ‘‘Federico II,’’ 80131 Napoli, Italy
5Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universita` di Napoli ‘‘Federico II,’’ 80131 Napoli, Italy
6Istituto di Genetica e Biofisica ‘‘A. Buzzati-Traverso’’ Consiglio Nazionale delle Ricerche (IGB-CNR), 80131 Napoli, Italy
7Dipartimento di Neuroscienze e Scienze Riproduttive e Odontostomatologiche, Universita` di Napoli ‘‘Federico II,’’ 80131 Napoli, Italy
8Dipartimento di Biologia, Complesso Universitario di Monte Sant’Angelo, Universita` di Napoli ‘‘Federico II’’, Napoli 80126, Italy
9Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
10Istituto di Scienze della Vita, Scuola Superiore Sant’Anna, 56127 Pisa, Italy
11Co-first author
*Correspondence: giuseppe.matarese@unina.it
http://dx.doi.org/10.1016/j.immuni.2016.01.028
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARY
Human CD4+CD25hiFoxp3+CD127 Treg and CD4+
CD25Foxp3 Tconv cell functions are governed
by their metabolic requirements. Here we report
a comprehensive comparative analysis between
ex vivo human Treg and Tconv cells that comprises
analyses of the proteomic networks in subcellular
compartments. We identified a dominant proteomic
signature at the metabolic level that primarily
impacted the highly-tuned balance between glucose
and fatty-acid oxidation in the two cell types. Ex vivo
Treg cells were highly glycolytic while Tconv cells
used predominantly fatty-acid oxidation (FAO).
When cultured in vitro, Treg cells engaged both
glycolysis and FAO to proliferate, while Tconv cell
proliferation mainly relied on glucose metabolism.
Our unbiased proteomic analysis provides amolecu-
lar picture of the impact of metabolism on ex vivo hu-
man Treg versus Tconv cell functions that might be
relevant for therapeutic manipulations of these cells.
INTRODUCTION
CD4+ T cells have been classified into different functionally
distinct subsets, on the basis of their cytokine production pat-
terns that generally associate with the expression of multiple
lineage-specific transcription factors (Bluestone et al., 2009).
Among those factors, the forkhead-box-P3 (FoxP3) transcription
factor is expressed by CD4+CD25+ regulatory T (Treg) cells, a406 Immunity 44, 406–421, February 16, 2016 ª2016 The Authorsspecialized subset of CD4+ T cells that suppresses proliferation
and effector cell functions in a wide range of immune target cells
(Sakaguchi et al., 2008; Min et al., 2003; Zheng et al., 2004; Kohrt
et al., 2010; Khazaie and von Boehmer, 2006). Human Treg cells
display a series of ‘‘apparent paradoxes’’ in their immunobiol-
ogy: they manifest in vitro hyporesponsiveness (anergy) to
T cell receptor (TCR) stimulation (Thornton and Shevach, 1998;
Li et al., 2005) although they have high surface expression of
activation markers and are highly proliferative in vivo (Vukma-
novic-Stejic et al., 2006; Vukmanovic-Stejic et al., 2008). In
contrast, CD4+CD25FoxP3 conventional T (Tconv) cells are
not hyporesponsive to TCR stimulation in vitro, but rapidly
respond to antigenic stimulation by increasing production of
interleukin-2 (IL-2) and/or cytokines that sustain their own prolif-
eration and clonal differentiation toward effector phenotypes.
Treg and Tconv cells have a high degree of plasticity that as-
sociates with a different regulation of their own transcriptional
programs. Over the past few years, advances have been
made in the understanding of the transcriptional regulation un-
derlying the gene-expression profiles of these cells (Schmidl
et al., 2014; Luo and Li, 2013; Painter et al., 2011). In particular,
the integration of multiple extracellular signals that directly
affect transcriptional programs and signaling pathways in
both cellular subsets have been linked to the induction of pro-
liferation, production of cytokines, and modulation of energy
metabolism. In this report, we mapped the proteome of either
freshly-isolated, in vitro-cultured, or TCR-activated human
Treg and Tconv cells to dissect their biochemical and metabolic
profiles and evaluate their dynamic changes upon different
in vitro culture conditions. Because the functions of Treg and
Tconv cells are regulated by specific metabolic pathways, the
full understanding of how they change according to specific
microenvironmental conditions and energy demands could
Figure 1. Freshly-Isolated Human Treg Cells Display a Glycolytic Metabolism whereas Tconv Cells Preferentially Use FAO
(A and B) Map of the interactome networks controlling the main biological processes/functions associated to metabolism (mitochondrial proteins, ribosome, lipid
metabolism and glycolysis), obtained by comparing the protein profile of freshly-isolated Tconv and Treg cells in themembranes (A) and in the cytoplasm (B). Red
(legend continued on next page)
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have major implications in integrative pathophysiology and hu-
man autoimmunity.
RESULTS
Freshly-Isolated Human Treg Cells Are Glycolytic,
whereas Tconv Cells Use Fatty-Acid Oxidation
The proteomic landscape of human Treg and Tconv cells was
assessed by analyzing protein expression according to their
subcellular compartmentalization (either cytosolic- or mem-
brane-associated). Highly stringent criteria in raw data handling
ensured the confident identification of 6,610 distinct peptides,
corresponding overall to 1,860 unique proteins. According to
the theoretical molecular weight (MW) and isoelectric point (pI),
the proteins identified were plotted in a 2D map using the Multi-
dimensional Algorithm Protein Map (MAProMa) software (Bram-
billa et al., 2012) (data not shown). The identified proteins,
including those differentially represented, were plotted into the
Global Mammalian Protein Interactomic (GMPI) network, using
the Cytoscape platform and its plugins (see Supplemental
Experimental Procedures for details).
To delineate the basal proteomic signature and networks
of human Treg and Tconv cells, we compared protein-expres-
sion profiles of the two freshly-isolated cell subsets, using Differ-
ential Average (Dave) and Differential Coefficient Index (DCI)
algorithms from MAProMa (Mauri et al., 2005). The differentially
expressed proteins are listed in Table S1A, Figure S1A, Table
S1B, and Figure S1B (membranes and cytosol, respectively).
Because the most representative functional classes that we
had found differentially expressed between freshly-isolated
Treg and Tconv cells were those associated with metabolism,
we analyzed this aspect at the protein, biochemical, and func-
tional levels. Proteomic analysis of freshly-isolated human
Treg cells indicated an upregulation of glycolysis-related
proteins (Figures 1A and 1B and Table S1C), such as glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH), phosphoglyc-
erate kinase 1 (PGK1) (in membranes) and transaldolase 1
(TALDO1), aldolase A (ALDOA), phosphoglycerate mutase 1
and 2 (PGAM1 and 2), enolase 1 (ENO1), and PGK1 (in the
cytosol), in agreement with the high proliferative profile of these
cells in vivo (Vukmanovic-Stejic et al., 2006; Vukmanovic-Stejic
et al., 2008). In contrast, Tconv cells expressed higher amounts
of mitochondrial proteins than Treg cells including enzymes ofplots correspond to specific proteins upregulated in Treg cells; blue plots corres
distributed proteins in the two cell compartments; white plots are the not-identifi
(C) Left, representative flow cytometry plots (percentage of Ki67+ cells indicated a
(one representative plot out of ten). Right shows percentage of Ki67+ cells from fre
independent experiments.
(D and E) ECAR in basal condition (D) and upon glucose injection (E) on freshly
experiments). The data are shown as mean ± SEM of three measurements, each
(F) OCR in freshly-isolated Tconv and Treg cells (one representative out of thr
measurements, each of them in duplicates.
(G) Percentage of FAO in freshly-isolated Tconv and Treg cells (one representative
three measurements, each of them in triplicates. (C–G) Statistical analysis by tw
(H and I) Immunoblot for aldolase, enolase, hexokinase, PKM1/2, FAS, ApoA4, HA
and total ERK 1/2 served as a loading control. One representative out of at least
tometric quantitation of aldolase, hexokinase, PKM1/2, enolase, FAS, ApoA4, HA
and Treg cells and shown as fold over Tconv cells (n = 6; data are shown as mean
by paired two-tailed Student’s t test (*p < 0.05, **p < 0.001, ***p < 0.0001).
408 Immunity 44, 406–421, February 16, 2016 ª2016 The Authorsthe Krebs tricarboxylic acid cycle (TCA) (isocitrate dehydroge-
nase [IDH2], aconitase 2 [ACO2], citrate synthase [CS], malate
dehydrogenase [MDH2], succinate dehydrogenase [SDHA]),
proteins involved in the mitochondrial respiratory electron trans-
port chain (electron transfer flavoprotein [ETFA], ubiquinol-cyto-
chrome c reductase I and II [UQCRC1 and 2]), in the anion chan-
nel formation (voltage-dependent anion channel 1, 2 and 3
[VDAC1, 2, and 3]), in the control of mitochondrial permeability
(solute carrier family 25 [SLC25A3]), and also mitochondrial pro-
teins devoted to production of ATP (H+-ATP synthase subunit b
[ATP5F1], ATP synthase H+ transporting [ATP5H]). In addition,
Treg cells had consistently higher amount of lipid metabolism-
associated proteins than Tconv cells, including apolipoprotein
B-100 (Apo B), apolipoprotein E (ApoE), apolipoprotein C-III pre-
cursor (APOC3), apolipoprotein A-I preproprotein (APOA1),
apolipoprotein A-IV precursor (APOA4), apolipoprotein C-II pre-
cursor (APOC2), apolipoprotein A-II preproprotein (APOA2),
clusterin isoform 2 preproprotein (CLU), and serpin peptidase in-
hibitor member 3 (Serpin A3).
To assess whether the proteomic signature associated with
specific differences of cellular metabolism, we performed func-
tional analyses (Seahorse assays), evaluating the bioenergetic
profiles of freshly-isolated Treg and Tconv cells. We confirmed
that Treg cells ex vivo were more proliferative than Tconv cells,
as testified by an increased expression of Ki67+cells in the
former compartment (Figure 1C). Next, we measured the extra-
cellular acidification rate (ECAR), an indicator of aerobic glycol-
ysis, in freshly-isolated Treg and Tconv cells, and found that
Treg cells had higher basal and glucose-stimulated ECAR (Fig-
ures 1D and 1E) than Tconv cells. In parallel, we found that O2
consumption rate (OCR), an indicator of oxidative phosphoryla-
tion (OXPHOS), was higher in Treg as compared to Tconv cells,
suggesting an increased mitochondrial functionality that might
possibly associate with an enhanced capacity of Treg cells to
adapt to an increased metabolic demand (Figure 1F). Finally,
fatty-acid b-oxidation (FAO) was evaluated by measuring OCR
resulting from exogenous addition of fatty acids (palmitate) to
cells, in the presence or in the absence of etomoxir (a specific in-
hibitor of FAO), to discriminate the fraction of OCR associated
with fatty acid utilization versus that derived from other sub-
strates. Tconv cells displayed higher FAO than Treg cells, sug-
gesting that non-proliferating cells mainly use FAO as an energy
source (Figures 1G and S1C).pond to proteins upregulated in Tconv cells; pink plots represent the equally
ed proteins.
bove the boxes) from freshly-isolated Tconv and Treg cells (SSC, side scatter)
shly-isolated Tconv and Treg cells. The data are shown as mean ± SEM of ten
-isolated Tconv and Treg cells (one representative out of three independent
of them in duplicates.
ee independent experiments). The data are shown as mean ± SEM of three
out of three independent experiments). The data are shown as mean ± SEM of
o tailed Mann-Whitney test. (*p < 0.05; **p < 0.005, ***p < 0.0005).
DHA, ACAD9, DLST, and SDHA on freshly-isolated Tconv and Treg cells. Actin
two independent experiments is shown. The graphs show the relative densi-
DHA, ACAD9, DLST, and SDHA normalized on actin in freshly-isolated Tconv
± SEM of two independent experiments, in triplicates). (H–I) Statistical analysis
Figure 2. Proteomic and Metabolic Profiles of In Vitro Anergic and Proliferating Human Treg Cells
Maps of the interactome networks controlling the main biological processes/functional classes associated to metabolism, obtained by comparing unstimulated
Treg cells with in vitro cultured Treg cells stimulated with anti-CD3 and anti-CD28 in the membranes (A) and in the cytosol (B), and by comparing anti-CD3 and
(legend continued on next page)
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These data were confirmed at the biochemical level (Figures
1H and 1I and S1D–S1G). The expression of glycolysis-related
enzymes (enolase, aldolase, pyruvate kinase 1/2 [PKM1/2]), as
well as lipid metabolism-related molecules (ApoA4 and fatty
acid synthase, FAS) was upregulated in Treg as compared to
Tconv cells. On the contrary, Tconv cells had an increased
expression of enzymes involved in FAO (hydroxyacyl-Coenzyme
A dehydrogenase [HADHA], and acyl-CoA dehydrogenase
[ACAD9]) and the TCA cycle (dihydrolipoamide succinyltransfer-
ase [DLST] and succinate dehydrogenase [SDHA]).
Distinct Proteomic and Metabolic Profiles of In Vitro
Anergic versus Proliferating Human Treg Cells
Treg cells proliferate in vivo (Vukmanovic-Stejic et al., 2006; Vuk-
manovic-Stejic et al., 2008) despite their anergic state in vitro (Li
et al., 2005). The reason for this discrepancy is little understood,
althoughmetabolism seems to play a role in this process, as indi-
cated by the evidence that overactivation of the mammalian
target of rapamycin (mTOR) pathway associates with human
Treg cell anergy (Procaccini et al., 2010; Procaccini and Matar-
ese, 2012). To determine whether in vitro culture conditions
could affect metabolic programs, we analyzed the proteomic
profile of Treg cells after 12 hr of culture in the presence or in
the absence of TCR-mediated stimulation with anti-CD3 and
anti-CD28 (Tables S2A–S2C and Figures S2A and S2B). Proteo-
mic analysis of in vitro (anergic) Treg cells revealed that in the
membrane compartment there was an unbalanced regulation
of mitochondrial proteins upon TCR stimulation (Figure 2A and
Table S2C). Indeed, IDH2, adenylate kinase 2 (AK2) (involved in
energy metabolism), MDH2 (citric acid cycle), NADH dehydroge-
nase 1 a subcomplex 10 (NDUFA10) (electron transfer), and
mitochondrial heat shock protein 60 (HSPD1) were upregulated
by TCR stimulation in Treg cells. In contrast, TCR stimulation
downregulated the expression of other mitochondrial proteins
(glutamate dehydrogenase 1 and 2 [GLUD1 and 2], mitochon-
drial ATP synthase subunit b [ATP5B], and mitochondrial
HSPA9 in the cytoplasm) (Figure 2B and Table S2C). Also, TCR
stimulation in Treg cells increased the expression of ribosomal
proteins in the membrane compartment, suggesting an induc-
tion of a high biosynthetic profile little impacting glycolysis.
For lipid-related metabolism, our analysis revealed that a
key enzyme of FAO, HADH (Figure 2B and Table S2C) was down-
regulated by TCR stimulation, whereas other proteins belonging
to the same functional class were upregulated by TCR stimula-
tion (3-hydroxyacyl-CoA dehydrogenase type-2 [HSD17B10],
delta(3,5)-delta(2,4)-dienoyl-CoA isomerase [ECH1], a-1-anti-
chymotrypsin [Serpin A3]) (Figure 2A and Table S2C). Moreover,
a decreased expression of several apolipoproteins (ApoE,
ApoC-3, ApoA4) was observed after TCR stimulation (Figures
2A and 2B and Table S2C).
We have previously shown that neutralization of the hormone-
cytokine leptin during activation of Treg cells reverses their aner-
gic state and sustains their own proliferation (De Rosa et al.,
2007). Here we compared the proteomic profile of in vitro anergicanti-CD28-stimulated Treg cells with leptin-neutralized Treg cells, in the memb
upregulated in anti-CD3 and anti-CD28-stimulated Treg cells; blue plots correspo
(A and B) and to proteins upregulated in leptin-neutralized-Treg cells (C) and (D)
conditions; white plots are the not-identified proteins.
410 Immunity 44, 406–421, February 16, 2016 ª2016 The Authorsversus proliferating Treg cells (Tables S3A–S3C and Figures S3A
and S3B). Treg cell proliferation (induced by leptin neutralization)
associated with an increased expression of glycolytic enzymes
both in the membrane (2-oxoglutarate dehydrogenase, L-lactate
dehydrogenase B chain, LDHB) and, more markedly, in the cyto-
plasm (L-lactate dehydrogenase a [LDHA] and b chain [LDHB],
PGAM1, TALDO1, triosephosphate isomerase [TPI1]) (Figures
2C and 2D and Table S3C). Moreover, several ribosomal pro-
teins were induced by leptin neutralization, in accordance with
increased protein synthesis in actively proliferating cells. More-
over, proliferating Treg cells upregulated the expression of
several apolipoproteins (ApoE, ApoA4, ApoA2) and proteins
associated with FAO (3-hydroxyacyl-CoA dehydrogenase
type-2 [HSD17B10], D(3,5)-D(2,4)-dienoyl-CoA isomerase, mito-
chondrial [ECH1], HADH) in the membrane and cytosol (Figures
2C and 2D and Table S3C). In contrast, proteins belonging to this
functional class (ApoA1, ApoA4, clusterin [CLU], ApoA2, ApoC1,
a-1-antichymotrypsin) were downregulated in the cytoplasm
(Figure 2D and Table S3C). With regard to mitochondrial pro-
teins, proliferating Treg cells increased the expression of
mitochondrial respiratory chain-associated proteins (NADH de-
hydrogenase a subcomplex 9 [NDUFA9], cytochrome b-c1 com-
plex subunit 1 [UQCRC1], SLC25A3) in the membranes and TCA
proteins (MDH2) and ATP synthase subunit b (ATP5B) in the
cytoplasm, indicating that Treg cells increasedmitochondrial ac-
tivity to sustain their own proliferation.
Human Treg Cell Proliferation In Vitro Requires Both
Glycolysis and Fatty-Acid Oxidation
Leptin neutralization in anti-CD3 and anti-CD28-activated Treg
cells reversed their anergy (Figure 3A), as indicated by in vitro
proliferation and induction of the extracellular signal-regulated
kinases 1 and 2 (ERK1/2) phosphorylation (Figure 3B). To eval-
uate the impact of glycolysis and FAO on Treg cell proliferation
in vitro, cells were cultured in the presence or in the absence
of specific inhibitors of glycolysis (2-deoxy-D-glucose, 2-DG)
and FAO (etomoxir) (Figure 3C). Addition of 2-DG and etomoxir
to proliferating Treg cells inhibited their expansion similarly, as
testified by the decreased 3H thymidine and bromodeoxyuridine
(BrdU) incorporation, thus suggesting the engagement of both
pathways in Treg cell proliferation in vitro (Figures 3C and 3D
and Figure S4A). Moreover, 2-DG and etomoxir treatment also
downregulated the expression of CD25 (in terms of mean fluo-
rescence intensity, MFI) in proliferating Treg cells (Figure S4B).
Reduced activation/proliferation of Treg cells, secondary to the
metabolic perturbations, were not associated with either altered
Treg cells survival or viability, as indicated by propidium iodide
(PI) and Annexin V (AV) staining (Figures S4C and S4D). We
also analyzed the bioenergetic profile of these cells evaluating
ECAR and OCR. Anergic (both unstimulated and TCR-stimu-
lated) Treg cells did not properly respond either to glucose,
oligomycin, or 2-DG treatment (Figure 3E). On the contrary,
proliferating Treg cells (induced by leptin neutralization) promptly
engaged glycolysis, as testified by a sharp increase in ECARranes (C) and in the cytosol (D). Red plots correspond to specific proteins
nd to proteins downregulated in anti-CD3 and anti-CD28-stimulated Treg cells
; pink plots represent the equally distributed proteins in the two experimental
(legend on next page)
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levels evaluated as basal, maximal ECAR (oligomycin-stimu-
lated) and glycolytic capacity (Figures 3E–3H); these data were
in agreement with their proteomic profile.
Because Treg cells proliferation had been obtained through
metabolic manipulation (leptin neutralization), we also evaluated
whether acute leptin neutralization during ECAR measurement
(Seahorse assays) could affect its profile. Specifically, we found
that ECAR levels were reduced by acute leptin neutralization
before TCR engagement (Figure 3I). These data suggest that
the inhibition of glycolysis before TCR stimulation (by leptin
neutralization) was necessary to render Treg cells responsive
to proliferative stimuli allowing the reversal of their anergic state
(Figure 3I).
Also, to assess whether leptin neutralization could influence
mitochondrial functions, we measured OCR in basal conditions,
after addition of oligomycin, carbonyl cyanide-4-(trifluorome-
thoxy) phenylhydrazone (FCCP), and antimycin-A/rotenone (to
inhibit electron transport chain, ETC) (Figure 3J). OCR was
induced following leptin neutralization, as indicated by an
increased basal, ATP-linked, and maximal respiratory capacity
in proliferating Treg cells, whereas all these parameters were
lower in unstimulated and TCR-stimulated Treg cells (Figures
3K–3M). Moreover, proliferating Treg cells had increased FAO
as compared to anergic (unstimulated and TCR-stimulated)
Treg cells, both in basal and maximal respiration conditions
(Figures 3N and 3O and S4E and S4F). Biochemical analysis
confirmed these data, showing an increased expression of
aldolase, enolase, and hexokinase (glycolytic enzymes), FAS,
ApoA4 (lipid metabolism-related proteins), and HADHA,
ACAD9, carnitine palmitoyltransferase 1A (CPT1A) (FAO en-
zymes) in proliferating Treg cells as compared to anergicFigure 3. Human Treg Cell Proliferation In Vitro Requires Both Glycoly
(A) In vitro proliferation of Treg cells upon 72 hr anti-CD3 and anti-CD28 stimulation
as mean ± SEM (n = 6).
(B) Immunoblot for P-ERK1/2 on human Treg cells upon 12 hr anti-CD3 and anti-CD
ERK1/2 served as a loading control. One representative out of three independen
(C) In vitro proliferation of Treg cells upon 72 hr anti-CD3 and anti-CD28 stimulatio
alone or in combination. The data are shown as mean ± SEM (n = 3).
(D) Fold inhibition of Treg cell proliferation upon leptin neutralization in the prese
(E) Kinetic profile of ECAR in Treg cells stimulated or not with anti-CD3 and anti-C
representative out of three independent experiments). The data are shown asmea
and in response to glucose, oligomycin and 2-DG. Indices of glycolytic pathway
ECAR (G), and glycolytic capacity (H) in Treg cells stimulated or not with anti-C
antibody (one representative out of three independent experiments). Data are ex
(I) ECAR profile of unstimulated Treg cells before and after leptin-neutralizing anti
data are shown as mean ± SEM of triplicates.
(J) Kinetic profile of OCR in Treg cells stimulated or not with anti-CD3 and anti-C
representative out of three independent experiments). The data are shown as mea
and in response to indicated mitochondrial inhibitors: oligomycin, FCCP, Antimy
from Treg cells OCR profile: basal OCR (K), ATP-linked OCR (L), andmaximal OCR
presence or absence of leptin-neutralizing antibody (one representative out of t
measurements, each of them in duplicates.
(N and O) Percentage of FAO in Treg cells stimulated or not with anti-CD3 and anti
was evaluated in basal conditions (N) and during maximal respiration (O) (one r
mean ± SEM of three measurements, each of them in duplicates.
(P) Immunoblot for aldolase, enolase, hexokinase, and PKM1/2, FAS, ApoA4,
stimulation in the presence or absence of leptin-neutralizing antibody. Actin and
dependent experiments is shown. The graphs show the relative densitometric q
ACAD9, and CPT1A normalized on actin in unstimulated (white columns), anti-CD
(black columns) and shown as fold over unstimulated Treg cells (n = 6; data are sh
statistical analysis by paired two-tailed Student’s t test. (*p < 0.05, **p < 0.001, *
412 Immunity 44, 406–421, February 16, 2016 ª2016 The Authors(both unstimulated and TCR-stimulated) Treg cells (Figures
3P and S4G–S4I). Moreover, we found that treatment with
2-DG or etomoxir in proliferating Treg cells partially blunted
the changes in the amount of aldolase (Figures S4J and S4K)
and HADHA (a FAO protein) (Figures S4L and S4M), induced
by leptin neutralization; this evidence confirmed specificity of
the phenomena.
Inhibition of Glycolysis and FAO Alters the Suppressive
Function of Human Treg Cells
To determine whether metabolic perturbations could associate
with a change in the regulatory function of human Treg cells,
we analyzed the expression of several Treg-lineage associated
markers (i.e., CD25, PD-1, and CTLA4) in unstimulated Treg cells
upon 12 hr pre-treatment with either 2-DG or etomoxir. The
expression of CTLA-4 and PD-1 was down-modulated by the
above treatments (Figure 4A), as compared to untreated Treg
cells (CTR), whereas slight differences were observed in CD25
expression (in terms of MFI). Next, Treg cells pre-treated with
2-DG or etomoxir were tested for their capability to suppress
in vitro CFSE-labeled Tconv cells proliferation in co-colture ex-
periments. Inhibition of glycolysis or FAO resulted in a significant
reduction (about 20%) of Treg cell suppressive function, as
compared to control Treg cells (Figure 4B).
To better understand the molecular mechanisms of the
above findings, we studied the effects of either 2-DG or
etomoxir on FoxP3 expression and cytokine-related- and cell
metabolism-associated signaling in Treg cells. FoxP3 expres-
sion was reduced in Treg cells treated with 2-DG or etomoxir,
as compared to control Treg cells (Figure 4C). Because
the IL-2-IL-2R signaling pathway has a pivotal role in thesis and FAO
in the presence or absence of leptin-neutralizing antibody. The data are shown
28 stimulation in the presence or absence of leptin-neutralizing antibody. Total
t experiments is shown.
n in the presence or absence of leptin-neutralizing antibody, 2-DG, or Etomoxir,
nce of 2-DG or Etomoxir. The data are shown as mean ± SEM (n = 3).
D28 for 12 hr, in the presence or absence of leptin-neutralizing antibody (one
n ± SEMof duplicates. ECARwasmeasured in real time, under basal conditions
activation, calculated from Treg cells ECAR profile: basal ECAR (F), maximal
D3 and anti-CD28 for 12 hr, in the presence or absence of leptin-neutralizing
pressed as mean ± SEM of three measurements, each of them in duplicates.
body injection (one representative out of three independent experiments). The
D28 for 12 hr, in the presence or absence of leptin-neutralizing antibody (one
n ± SEM of duplicates. OCRwasmeasured in real time, under basal conditions
cin A and Rotenone. Indices of mitochondrial respiratory function, calculated
(M) in Treg cells stimulated or not with anti-CD3 and anti-CD28 for 12 hr, in the
hree independent experiments). Data are expressed as mean ± SEM of three
-CD28 for 12 hr in the presence or absence of leptin-neutralizing antibody. FAO
epresentative out of three independent experiments). Data are expressed as
HADHA, ACAD9, CPT1A, on Treg cells upon 12 hr anti-CD3 and anti-CD28
total ERK 1/2 served as a loading control. One representative out of two in-
uantitation of aldolase, enolase, hexokinase, PKM1/2, FAS, ApoA4, HADHA,
3, and anti-CD28-stimulated (gray columns) and leptin-neutralized Treg cells
own as mean ± SEM of at least two independent experiments, in triplicates). All
**p < 0.0001).
Figure 4. Suppressive Function of Human Treg Cells Requires Both Glycolysis and FAO
(A) Representative flow cytometry plots showing expression of lineage specific markers (CTLA-4, PD-1, CD25) in Treg cells upon 12 hr pretreatment with vehicle
(CTR), 2-DG, or etomoxir. Percentage and MFI of positive cells are indicated. One representative out of three independent experiments is shown.
(B) Percentage of inhibition of CFSE-labeled Tconv cell proliferation co-cultured for 72 hr with Treg cells pre-treated 12 hr with vehicle, 2-DG, or etomoxir. The
data are shown as mean ± SEM and are expressed as reduction over CTR (n = 8).
(C) Immunoblot for FoxP3, actin, total ERK1/2, P-STAT5, STAT5, P-S6, and S6 on Treg cells upon 12 hr anti-CD3 and anti-CD28 stimulation in the presence or
absence of 2-DG or etomoxir. One representative out of two independent experiments is shown. The graphs show the relative densitometric quantitation of
FoxP3 (normalized on actin and total ERK 1/2), P-STAT5 (normalized on total STAT5), and P-S6 (normalized on total S6) (n = 6, data are shown as mean ± SEM of
two independent experiments, in triplicates). All statistical analysis by paired two-tailed Student’s t test (*p < 0.05, **p < 0.005).generation, in vivo proliferation, and function of Treg cells (Tang
et al., 2008; Long et al., 2010; Cheng et al., 2011; Cheng et al.,
2013), we evaluated Signal Transducer and Activator of Tran-
scription-5 (STAT-5) phosphorylation as the major element of
transduction for IL-2R. 2-DG and etomoxir markedly reduced
STAT-5 phosphorylation in Treg cells stimulated for 12 hr
with anti-CD3 and anti-CD28 (Figure 4C). This phenomenon
was accompanied by a reduced phosphorylation of the ribo-
somal protein S6, a downstream target of mTOR, whose activ-
ity is pivotal for Treg cell biology (Zeng et al., 2013; Procaccini
et al., 2010) (Figure 4C).
Proteomic and Metabolic Profiles of In Vitro Cultured
Human Tconv Cells
The proteomic profile of Tconv cells, in basal conditions and after
TCR stimulation or metabolic manipulation, through leptin
neutralization, was also evaluated (Tables S4 and S5 and Figures
S5 and S6). Glycolytic enzymes (ENO1, TPI1, ALDOA, PGMA1,
and PGK2) were strongly upregulated by TCR stimulation,
particularly in the cytoplasm (Figure 5B and S5B and Tables
S4B and S4C) and the same occurred for apolipoproteins
(ApoE, ApoA4, ApoC3). In the membrane compartment, TCR
stimulation in Tconv cells induced the expression of several ribo-
somal proteins, in agreement with induction of protein synthesis
and proliferation (Figures 5A and S5A and Tables S4A and S4C).
This phenomenon was associated with a reduction of several
mitochondrial proteins (VDAC3, ATP5F1, ATP5H), namely those
connected to the Krebs cycle (CS, SDHA) and mitochondrial
permeability transition (SLC25A3), together with a reduction ofFAO enzyme (HADH) (Figures 5A and S5A and Tables S4A and
S4C).
We have reported that metabolic manipulation, through leptin
neutralization had opposite effects on Treg and Tconv cells,
because it induces Treg cell proliferation while it inhibits Tconv
cell proliferation (De Rosa et al., 2007). We found that leptin
neutralization of Tconv cells associated with a consistent reduc-
tion of ribosomal proteins in membranes, as well as a decreased
expression of mitochondrial proteins associated with electron
transport chain (SDHA, ATP synthase beta chain [ATP5B],
VDAC1 and VDAC3) or TCA cycle (MDH2), both in themembrane
and in the cytoplasm (Figures 5C and 5D and S6A and S6B and
Tables S5A–S5C). Inhibition of Tconv cell proliferation by leptin
neutralization reduced a fraction of glycolytic enzymes such as
ALDOA and PGK1 and 2 but upregulated other intermediates
such as LDHB, TPI1, GAPDH, and ENO3 (Figures 5C and 5D
and S6A and S6B and Tables S5A–S5C).
With regard to lipid metabolism, in the membrane compart-
ment leptin neutralization downregulated the expression of
FAO-associated proteins (hydroxysteroid [17-beta] dehydroge-
nase 4 [HSD17B4], HADHA) and apolipoproteins (ApoB), but up-
regulated the expression of other proteins of the same functional
class (annexin A I [ANXA1], mitochondrial short-chain enoyl-CoA
hydratase [ECHS1], ApoA1, ApoA4, ApoA2) (Figures 5C and S6A
and Tables S5A and S5C). In the cytoplasm, leptin neutralization
downregulated the expression of ApoC3 and ApoA4 and
increased the expression of ApoA2, Serpin A3, and leukotriene
A4 hydrolase (LTA4H) (Figures 5D and S6B and Tables S5B
and S5C).Immunity 44, 406–421, February 16, 2016 ª2016 The Authors 413
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Human Tconv Cell Proliferation In Vitro Requires
Glycolysis but Not Fatty-Acid Oxidation
TCR stimulation of Tconv cells induced their proliferation associ-
ated with the phosphorylation of the ERK1/2 kinases (Figures 6A
and 6B), whereas leptin neutralization was able to inhibit their
proliferation. Culture of Tconv cells in the presence or in the
absence of 2-DG and etomoxir showed that the inhibition of
glycolysis strongly reduced Tconv cell proliferation (evaluated
by 3H thymidine incorporation and BrdU staining) (Figures 6C
and 6D and S7A), also in terms of CD25 expression (Figure S7B),
without affecting their viability (Figures S7C and S7D), with an
additive effect on inhibition mediated by leptin neutralization.
Conversely, inhibition of FAO with etomoxir did not affect Tconv
cell proliferation and survival, suggesting that these cells prefer-
entially use glycolysis to sustain their own proliferation (Figures
6C and 6D and Figures S7A–S7D).
Confirming the above data, TCR stimulation induced an in-
crease in basal, maximal ECAR, and glycolytic capacity in Tconv
cells, whereas leptin neutralization inhibited these parameters
(Figures 6E–6H). Interestingly, basal, ATP-linked, and maximal
OCR were upregulated during Tconv cell activation but leptin
neutralization inhibited their TCR-mediated induction (Figures
6I–6L). Concomitantly, Tconv cell activation with anti-CD3 and
anti-CD28 associated with a strong reduction of FAO as
compared to unstimulated Tconv cells. Leptin neutralization
had no effect on the modulation of this pathway, suggesting
that Tconv cells did not use FAO to sustain ATP production
and proliferation, but rather switched T cell metabolism from
FAO to aerobic glycolysis (Figures 6M and 6N and S7E and S7F).
Finally, we confirmed the above data at the biochemical level
by Western blotting (Figures 6O and S7G–S7I). TCR stimulation
induced aldolase, enolase, and PKM1/2 (glycolytic enzymes)
and FAS, whereas ACAD9, CPT1A, and HADHA (all involved
in FAO) were downregulated by TCR-mediated activation. In
agreement with the metabolic data, leptin neutralization reduced
the expression of glycolytic enzymes but had little effect on FAO
modulation (Figures 6O and S7G–S7I). Of note, the inhibition of
glycolytic and FAO proteins induced by leptin neutralization
has been confirmed by treatment with 2-DG or etomoxir, which
equally inhibited their expression (Figures S7J–S7M).
Effector Functions of Human Tconv Cells Are Mainly
Sustained by Glycolysis
To study the effects of either glycolysis or FAO inhibition on
Tconv cell function, we evaluated the expression of several acti-
vation markers (i.e., CD25, CD127, CD71, ICAM-1, VLA-4, and
CTLA-4) on Tconv cells upon TCR stimulation, in the presence
or the absence of etomoxir or 2DG, respectively (Figure 7A). As
for proliferation, 2-DG treatment reduced expression of all these
markers while etomoxir only affected expression of ICAM-1 and
VLA-4, suggesting that Tconv cell activation mainly relies onFigure 5. Proteomic and metabolic profiles of in vitro-cultured human
Maps of the interactome networks controlling the main biological processes/func
Tconv cells with in vitro cultured Tconv cells stimulated with anti-CD3 and anti-C
and anti-CD28-stimulated Tconv cells with leptin-neutralized Tconv cells, in th
proteins upregulated in anti-CD3 and anti-CD28-stimulated Tconv cells; blue plot
Tconv cells (A) and (B) and to proteins upregulated in leptin-neutralized Tconv c
experimental conditions; white plots are the not-identified proteins.glycolysis. Consistent with the reduced proliferation and activa-
tion of Tconv cells, inhibition of glycolysis associated with a
decreased production of pro-inflammatory cytokines, such as
IL-2 and IFN-g, whereas etomoxir had a little impact on the
secretion of these cytokines by Tconv cells (Figure 7B).
We next evaluated the activity of the main biochemical path-
ways related to T cell cycle/proliferation, IL-2-IL-2R signaling
andmTOR pathway in Tconv cells, upon TCR-mediated stimula-
tion in the presence or the absence of etomoxir or 2-DG
(Figure 7C). As for the previous parameters, 2-DG treatment
significantly reduced the phosphorylation of ERK1/2, S6, and
STAT5, when compared to anti-CD3 and anti-CD28-activated
Tconv cells, whereas etomoxir did not affect significantly their
phosphorylation (Figure 7C).
Finally, in order to dissect the effects of glycolysis and FAO on
Tconv cell metabolism, we also performed Seahorse experi-
ments in Tconv cells chronically treated with 2-DG or etomoxir.
ECAR profile of activated Tconv cells was not affected by
12 hr treatment with etomoxir, differently from what observed
with 2-DG (Figures S7N–S7Q). At the same time, FAO rate of
activated/proliferating Tconv cells was comparable to that of
etomoxir-treated Tconv cells, in which FAO was chronically in-
hibited. On the contrary, inhibition of glycolysis with 2-DG
enhanced FAO. Taken together, these data suggest that FAO
only marginally participates to Tconv cell activation/proliferation
(Figures S7R–S7U), as they are more sensitive to inhibition of
glycolysis, which represents the main metabolic pathway in the
control of their function.
DISCUSSION
Understanding the impact of basic metabolic pathways on the
development and function of immune cells is of great interest
in immunological research. Our study illustrates a proteomic
andmetabolic comparison between human Treg and Tconv cells
in both unmanipulated (freshly-isolated) and in vitro culture con-
ditions. This study identified (1) ex vivo metabolic programs
associated with cell lineage commitment and diversification; (2)
the differential impact of metabolism on the proteomic network
and its dynamic changes occurring in in vitro cultured Treg
versus Tconv cells; (3) the impact of metabolism on Treg and
Tconv cell function; and (4) metabolic regulation of human Treg
cell homeostasis. Our findings unveil the metabolic signature
of ex vivo human Treg and Tconv cells and provide evidence
of how these cells can adapt their metabolic requirements ac-
cording to the in vitro microenvironmental cues to support their
specific functions. This might have major implications in under-
standing the impact of metabolism on immune tolerance, both
in physiological conditions and in autoimmunity.
To identify the proteomic networks associatedwith the biology
of human Treg and Tconv cells, we performed proteomicTconv cells
tional classes associated to metabolism, obtained by comparing unstimulated
D28 in the membranes (A) and in the cytosol (B), and by comparing anti-CD3
e membranes (C) and in the cytosol (D). Red plots correspond to specific
s correspond to proteins downregulated in anti-CD3 and anti-CD28-stimulated
ells (C) and (D); pink plots represent the equally distributed proteins in the two
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Figure 6. Human Tconv Cell Proliferation In Vitro Requires Glycolysis but Not FAO
(A) In vitro proliferation of Tconv cells upon 72 hr anti-CD3 and anti-CD28 stimulation in the presence or absence of leptin-neutralizing antibody. The data are
shown as mean ± SEM (n = 6).
(B) Immunoblot for P-ERK1/2 on human Tconv cells upon 12 hr anti-CD3 and anti-CD28 stimulation in the presence or absence of leptin-neutralizing antibody.
Total ERK1/2 served as a loading control. One representative out of three independent experiments is shown.
(C) In vitro proliferation of Tconv cells upon 72 hr anti-CD3 and anti-CD28 stimulation in the presence or absence of leptin-neutralizing antibody, 2-DG, or
etomoxir, alone or in combination. The data are shown as mean ± SEM (n = 3).
(D) Fold inhibition in Tconv cells proliferation upon TCR-mediated stimulation in the presence of 2-DG and etomoxir. The data are shown as mean ± SEM (n = 3).
(legend continued on next page)
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profiling in unmanipulated, freshly-isolated cells. We suggest
that the main changes in protein profiles between human Treg
and Tconv cells can be attributed to a different fitness in their
metabolic asset (MacIver et al., 2013). Michaleck and colleagues
showed that although Th1 and Th17 cells (which express high
amounts of the glucose transporter Glut1) are highly glycolytic,
Treg cells generated through in vitro polarization of CD4+
T cells preferentially use lipid oxidation (Michalek et al., 2011;
Gerriets et al., 2015). Because those differentiating conditions
were induced in vitro by addition of high doses of cytokines
(TGF-b), we investigated the metabolism associated with unma-
nipulated, freshly-isolated human Treg and Tconv cells. We
found that unmanipulated human Treg cells were highly glyco-
lytic at the proteomic, biochemical, and functional level as
compared to Tconv cells. Because glycolysis is believed to
promote biosynthesis for rapid T cell growth, this result is in
agreement with previous finding showing that Treg cells actively
proliferate in vivo both in humans and in mice (Vukmanovic-
Stejic et al., 2006; Vukmanovic-Stejic et al., 2008) and are also
metabolically more active than Tconv cells, expressing higher
level of mammalian-target of rapamycin (mTOR) (Procaccini
et al., 2010)—whose activity associates with high glycolytic
levels (Tandon et al., 2011; Cheng et al., 2014). Glycolysis is
important for generation of inducible Treg (iTreg) cells via the in-
duction of specific Foxp3 splicing variants (De Rosa et al., 2015).
In this context, human Treg cells can acidify the medium, even in
the absence of exogenous glucose, because of the high lactate
production following proliferation in vivo; as consequence of this
state, upon injection of glucose, glycolysis is further increased in
Treg cells, reaching levels which were always higher than Tconv
cells.
Our finding is in line with previous data that showed that Treg
cells produce high amounts of leptin and express high level of
leptin receptor (LepR) (De Rosa et al., 2007). LepR activation in-
duces glucose uptake and license metabolically CD4+ T cells for
proliferation. We also found that freshly-isolated human Treg
cells displayed higher amount of apolipoprotein when compared
with Tconv cells, in agreement with the finding that T cell prolif-
eration also requires glycolytic-lipogenic metabolic pathways(E) Kinetic profile of ECAR in Tconv cells stimulated or not with anti-CD3 and anti-
representative out of three independent experiments). The data are shown asmea
and in response to glucose, oligomycin, and 2-DG. Indices of glycolytic pathway a
(G), and glycolytic capacity (H) in Tconv cells stimulated or not with anti-CD3 and
(one representative out of three independent experiments). Data are expressed
(I) Kinetic profile of OCR in Tconv cells stimulated or not with anti-CD3 and anti-C
representative out of three independent experiments). The data are shown as mea
and in response to indicated mitochondrial inhibitors: oligomycin, FCCP, Antimy
from Tconv OCR profile: basal OCR (J), ATP-linked OCR (K), maximal OCR (L)
presence or absence of leptin-neutralizing antibody (one representative out of t
measurements, each of them in triplicates.
(M and N) Percentage of FAO in Tconv cells stimulated or not with anti-CD3 and
FAO was evaluated in basal conditions (M) and during maximal respiration (N) (on
mean ± SEM of three measurements, each of them in duplicates.
(O) Immunoblot for Aldolase, Enolase, Hexokinase, and PKM1/2, Fatty acid syntha
and anti-CD28 stimulation in the presence or absence of leptin-neutralizing antibo
of three independent experiments is shown. The graphs show the relative densit
HADHA, ACAD9, and CPT1A normalized on actin in unstimulated (white column
Tconv cells (black columms) and shown as fold over unstimulated Tconv cells.
triplicates). All statistical analysis by paired two-tailed Student’s t test. (*p < 0.05(Berod et al., 2014). These findings resemble themetabolic asset
of activated CD4+ T cells, which rely on glycolysis for de novo
fatty-acids synthesis to support the need for membrane synthe-
sis required for proliferation. In this context, the high amount of
apoA-IV proteins expressed by Treg cells further supports the
anti-inflammatory and anti-atherogenic role of apolipoproteins
(Vowinkel et al., 2004; Bellemore et al., 2014; Nilsson et al.,
2012; Wilhelm et al., 2010). Finally, we observed higher mito-
chondrial respiration in freshly-isolated Treg cells, possibly asso-
ciated with their enhanced capability to respond to metabolic
demand. Instead, freshly-isolated Tconv cells expressed high
levels of TCA cycle-associated proteins and used FAO to sustain
proliferation, reinforcing the notion that resting Tconv cells main-
tain low rates of glycolysis and predominantly use FAO to pro-
duce ATP (MacIver et al., 2013; Maciolek et al., 2014).
Treg cell biology is strictly linked to adipose tissue homeosta-
sis. In this context leptin, an adipose-tissue-derived cytokine,
constrains Treg cell proliferation by activating the mTOR
pathway and inducing TCR hyporesponsiveness (De Rosa
et al., 2007). Leptin neutralization reversed anergy and induced
Treg cell proliferation while inhibiting Tconv proliferation (De
Rosa et al., 2007). Because of those data, we used leptin neutral-
ization for in vitro expansion of Treg cells concomitantly to inhibit
Tconv proliferation. This approach allowed us to analyze the
metabolic changes of Treg and Tconv cells in different culture
conditions and TCR stimulation.We found that anergic Treg cells
expressed high amounts of ribosomal proteins, suggesting an
active biosynthetic activity accompanied by the maintenance
of a high glycolytic rate (also supported by high mTOR activity)
not associated with FAO. In contrast, in vitro Treg cell prolifera-
tion, induced by leptin neutralization, required activation of both
glycolysis and FAO. At the functional level, we observed that
glycolysis and FAO inhibition downregulated the expression of
FoxP3 and other specific Treg cell markers, reducing their
suppressive activity. At the molecular level, these events associ-
ated with functional impairment of IL-2-IL-2R-STAT5 signaling
pathway, in line with reports showing that IL-2 signaling is essen-
tial for functional maturation of Treg cells, through activation of
STAT5 (Cheng et al., 2011, Cheng et al., 2013; Burchill et al.,CD28 for 12 hr, in the presence or absence of leptin-neutralizing antibody (one
n ± SEM of triplicates. ECARwasmeasured in real time, under basal conditions
ctivation, calculated from Tconv ECAR profile: basal ECAR (F), maximal ECAR
anti-CD28 for 12 hr, in the presence or absence of leptin-neutralizing antibody
as mean ± SEM of three measurements, each of them in triplicates.
D28 for 12 hr, in the presence or absence of leptin-neutralizing antibody (one
n ± SEM of triplicates. OCR was measured in real time, under basal conditions
cin A, and Rotenone. Indices of mitochondrial respiratory function, calculated
in Tconv cells stimulated or not with anti-CD3 and anti-CD28 for 12 hr, in the
hree independent experiments). Data are expressed as mean ± SEM of three
anti-CD28 for 12 hr in the presence or absence of leptin-neutralizing antibody.
e representative out of three independent experiments). Data are expressed as
se (FAS), ApoA4, HADHA, ACAD9, CPT1A on Tconv cells upon 12 hr anti-CD3,
dy. Actin and total ERK 1/2 served as a loading control. One representative out
ometric quantitation of Aldolase, Enolase, Hexokinase, PKM1/2, FAS, ApoA4,
s), anti-CD3 and anti-CD28-stimulated (gray columns), and leptin-neutralized
(n = 6; data are shown as mean ± SEM of two independent experiments, in
, **p < 0.001, ***p < 0.0001).
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Figure 7. Effector Functions of Human Tconv Cells Are Mainly Sustained by Glycolysis
(A) Representative flow cytometry plots showing expression of activation markers (CD25, CD127, CD71, ICAM-1, VLA-4, and CTLA-4) in Tconv cells upon 36 hr
activation with anti-CD3 and anti-CD28 in the presence or absence of 2-DG or etomoxir. Percentage and MFI of positive cells are indicated. One representative
out of two independent experiments is shown.
(B) MFI of IL-2 and IFN-g expression in Tconv cells stimulated for 12 hr with anti-CD3 and anti-CD28 in the presence or absence of 2-DG or etomoxir, analyzed by
flow cytometry. Data are expressed as mean ± SEM (n = 3).
(C) Immunoblot for P-ERK 1/2, P-STAT5, and P-S6 on Tconv cells upon 12 hr anti-CD3 and anti-CD28 stimulation in the presence or absence of 2-DG or etomoxir.
Total ERK 1/2, total STAT5, and total S6 served as a loading control. One representative out of two independent experiments is shown. The graphs show the
relative densitometric quantitation of each phosphorylated protein normalized on its total form, in Tconv cells treated for 12 hr with anti-CD3 and anti-CD28 in the
presence or absence of 2-DG or etomoxir (n = 6, data are shown as mean ± SEM of two independent experiments, in triplicates). All statistical analysis by paired
two-tailed Student’s t test (*p < 0.05, **p < 0.005).2007), which is a critical factor in the induction and maintenance
of FoxP3 expression (Passerini et al., 2008, Carbone et al., 2014).
The mTOR pathway controls TCR-dependent FoxP3 expres-
sion (Sauer et al., 2008). The anergic state and suppressive func-
tion of Treg cells in vitro partly depended on their high metabolic
rate, associated with mTOR pathway activation. Here we
observed that reduced Treg cell suppressive capacity, induced
by 2-DG and etomoxir, associated with an impairedmTOR activ-
ity, thus suggesting that the metabolic control is crucial for Treg
cell functions. Of note, Tconv cells had an opposite behavior,
because they preferentially used glycolysis to sustain their prolif-
eration, while reducing FAO, in line with recent findings showing
that Th1 and Th17 pathogenic cells require glycolysis to allow full
differentiation (Gerriets et al., 2015). Functionally, inhibition of
glycolysis impaired Tconv cell activation by downmodulating
ERK1 and ERK2 and STAT5 and S6 phosphorylation and modu-
lating effector functions through reduction of pro-inflammatory
cytokines.418 Immunity 44, 406–421, February 16, 2016 ª2016 The AuthorsTaken together, our data suggest that Treg cells are highly
sensitive to metabolic perturbations as compared to Tconv cells.
Glycolysis in Treg cells made them unresponsive to proliferative
stimuli in vitro. A transient inhibition of glycolysis reversed Treg
cell anergy, restoring responsiveness to TCR activation; this is
in agreement with the finding that transient mTOR inhibition
could reverse Treg cell anergy and with the work showing that
knocking downGlut1 increased Treg cell expansion in vivo (Mac-
intyre et al., 2014).
To summarize, this study shows that (1) Treg cells are very
sensitive to metabolic demand and are highly glycolytic
ex vivo; (2) Treg cell anergy in vitro is associated with high
glycolysis, since its transient inhibition (through leptin neutrali-
zation) reverses this state; and (3) in vitro proliferation and func-
tion of Treg cells require both glycolysis and FAO, whereas
those of Tconv cells require only glycolysis. The discrepancy
between ex vivo and in vitro data raised the question of whether
in vitro metabolic manipulations (i.e., additions of high doses of
cytokines) might have a possible impact on the way in which hu-
man Treg cells are usually expanded in vitro for possible thera-
peutic potential. A recent report showed that in a phase I study,
the adoptive transfer of autologous ex vivo-expanded human
Treg cells from type I diabetes patients had no therapeutic effect
on their metabolic dysfunction and C-peptide production, insu-
lin use and hemoglobin A1c (HbA1c) levels (Bluestone et al.,
2015). It was suggested that the progressive decline in circu-
lating Treg cells after transfer could be ascribed to cell death
linked to reduced IL-2 signaling associated with the shift from
in vitro to in vivo (Bluestone et al., 2015). Our data suggest
engagement of different metabolic pathways during the expan-
sion of Treg cells in vivo versus in vitro and different metabolic
and proteomic profiles under the two conditions. As such, our
report identifies potential metabolic regulators of Treg and
Tconv cell proliferation and responsiveness to stimulation that
could unveil networks relevant for the control of T cell homeo-
stasis and function.
EXPERIMENTAL PROCEDURES
Cell Purification, Cultures, and Proliferation Assays
The study was approved by the Institutional Review Board (IRB) of the Univer-
sita` degli Studi di Napoli ‘‘Federico II.’’ Buffy coats from control healthy
subjects were obtained after they signed an IRB-approved written
informed consent. We isolated human Treg (CD4+CD25highCD127) and
Tconv (CD4+CD25) cells from PBMCs from buffy coats of human healthy do-
nors by high-performance cell sorting (MoFlo, Dako Beckman-Coulter or BD
FACS-Jazz, BD Bioscience) in the IEOS-CNR Sorting Facility in Napoli, after
staining with the following antibodies at 1:100 dilution: FITC anti-human CD4
(BD PharMingen, clone RPA-T4, Cat.# 555346), PE anti-human CD25 (BD
PharMingen, clone M-A251 Cat.# 555432) and APC anti-human CD127
(R&D Systems, clone 40131, Cat.# FAB306A), or by magnetic cell separation
with Dynabeads Regulatory T Cell Kit (Invitrogen). Soon after isolation, we
rapidly cleaned Treg with Detach reagent (Invitrogen), which removes
surface-bound CD25 mAb, and washed them extensively. These CD25-anti-
body-free Tregs were 95%–98% pure by FACS analysis, and > 95% ex-
pressed FoxP3. We cultured cells (2 3 104 cells per well) in round-bottom
96-well plates (Becton Dickinson Falcon) with RPMI 1640 medium supple-
mented with 100 UI/ml penicillin and 100 mg/ml streptomycin (all from Life
Technologies) and 5% AB human serum (Sigma-Aldrich). Cells were stimu-
lated for 3 days in the presence of anti-CD3 and anti-CD28-coated Dynabeads
(0.1 beads per cell) (Invitrogen). For in vitro leptin blocking experiments, we
used human anti-leptin neutralizing mAb (clone 44802, Cat.# MAB398, R&D
Systems) at a final concentration of 20 mg/ml. 2-Deoxy-D-glucose (2DG)
(Sigma-Aldrich) was used at final concentration of 1 mM; etomoxir was pur-
chased from Sigma-Aldrich and it was used at the final concentration of
200 mM. On the last day (60–72 hr), we added [3H] thymidine (0.5 mCi per
well) (Amersham-Pharmacia Biotech) to the cultures and harvested cells after
12 hr (Tomtec). Radioactivity was measured with a beta-plate scintillation
counter (Wallac).
Sample Preparation for Multidimensional Protein Identification
Technology Analysis
We stimulated freshly-isolated Tconv and Treg cells either with anti-CD3 and
anti-CD28-coated Dynabeads (0.2 beads per cell) (Invitrogen) alone or anti-
CD3 and anti-CD28 and anti-leptin-neutralizing mAb for 12 hr. We performed
two independent sample preparations for multidimensional protein identifica-
tion technology (MudPIT) analyses, consisting of 13 106 cells per preparation,
each deriving from a pool of four independent experiments of Tconv/Treg
purifications from different healthy donors. Briefly, total cell lysates were
obtained in 50 ml of 50 mM NH4HCO3 and 150 mM NaCl buffer (pH 7.5). Mem-
brane and cytosolic proteins were separated by centrifugation to obtain pellet
and supernatant protein samples, respectively. Total protein was quantified
using the Bio-Rad protein assay (Bio-Rad).Tryptic Digestion and Mass Spectrometry
Digestion, detailed mass spectrometry procedures, and data handling for pro-
teomic and network analysis were performed as described in Supplemental
Experimental Procedures.
Flow Cytometry, CFSE, and BrdU Staining
For staining of freshly isolated Treg and Tconv and their immunophenotype we
used (1:50–100 dilution) Pe-Cy5-labeled anti-CD4 (BD Biosciences, clone
RPA-T4, Cat.# 555348), APC-labeled anti-human CD25 (BD Biosciences,
clone M-A251, Cat.# 555434), APC anti-human CD71 (BD PharMingen, clone,
M-A712 Cat.# 551374), PercP-Cy5.5 anti-human CD127 (BD PharMingen,
clone HIL-7R-M21, Cat.# 560551), APC anti-human CD152 (BD PharMingen,
clone BNI3 Cat.# 555855), PerCP-Cy5.5 anti-human CD279 (PD-1) (BD Phar-
Mingen, clone EH12.1 Cat.# 581273). Thereafter, we washed, fixed and per-
meabilized cells (fixation-permeabilization buffer, eBioscience) and stained
with PE-labeled anti-FoxP3 (eBioscience, clone PCH101, Cat.#12-4776) and
FITC-labeled anti-Ki67 (BDBiosciences, clone B56, Cat.# 556026)monoclonal
antibodies. Flow cytometry experiments were performed with a BD FACS-
Canto and analyzed with Diva software from BD and FlowJo software (Tree
Star).
Incorporation of Bromodeoxyuridine (BrdU) and FACS analysis were per-
formed with the BrdU Flow Kit (BD-PharMingen) in accordance to the manu-
facturer’s instructions. The fluorescent dye CFSE (5, 6-carboxyfluorescein
diacetate succinimidyl ester) was used at 1 mg/ml (Invitrogen). Flow cytometric
analysis of CFSE dilution was performed by gating on CD4+CFSE+ cells
stimulated for 96 hr with anti-CD3 and anti-CD28 Dynabeads (0.5 beads/
cell) (Invitrogen) alone or co-cultured with Treg cells pre-treated or not with
2-DG or etomoxir for 12 hr.
Mitochondrial Bioenergetics and Metabolic Assays
The metabolic profiles have been evaluated as described in Supplemental
Experimental Procedures.
Western Blot Analyses
Total cell lysates and Western blot analysis were performed as previously
described (De Rosa et al., 2007). The antibodies used were the following:
anti-aldolase, anti-enolase, anti-hexokinase, anti-PKM1/2, anti-FAS, anti-
apoA4, anti-HADHA, anti-ACAD9, anti-CPT1A, anti-DLST, anti-SDHA, anti-
phospho STAT5, anti-STAT5, anti-phospho-S6, anti-S6 (all 1:1000 dilution
and from Cell Signaling Technology), anti-FoxP3 (1:500 dilution from eBio-
science). anti-ERK1/2 (1:500 dilution) and anti-phospho-ERK1/2 (1:500 dilu-
tion) (from Santa Cruz Biotechnology), The filters were also probed with an
actin antibody (1:1000 from Santa Cruz) to normalize for the amount of loaded
protein. All filters were quantified as previously described (De Rosa et al.,
2007).
SUPPLEMENTAL INFORMATION
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